A nurse has a syringe containing a vaccine against coronavirus disease (COVID-19) manufactured by the Beijing Institute of Biological Products, a unit of China National Biotec Group (CNBG), a subsidiary of Sinopharm, in a vaccination center during a government-organized visit to Beijing. , China, April 15, 2021. REUTERS / Thomas Peter
The World Health Organization will decide later this month or in May on the emergency listings for COVID-19 vaccines from Sinopharm (1099.HK) and Sinovac (SVA.O) following an expanded review, said an official from the WHO European region on Thursday.
“We are in contact with them to review the dossiers submitted by the two vaccine manufacturers,” Siddhartha Datta, WHO-Europe vaccination expert, told a virtual press conference. “We will hear a decision on the emergency use list in April or early May, so please stay tuned for that.”
A WHO group in the final stages of reviewing Chinese vaccines has said a decision of at least one could be reached on April 26, while a second meeting is scheduled for May 3, in case of needing more time to make a decision on both shots.
This WHO emergency list is a prerequisite for the purchase by the COVAX shared vaccine team designed to shoot at the poorest countries. It also helps guide countries with less developed regulatory systems on the safety and effectiveness of a vaccine.
To date, the WHO has published emergency lists for the COVID-19 vaccine from Pfizer and BioNTech (22UAy.DE), as well as versions of the AstraZeneca vaccine (AZN.L) developed by the Serum Institute of the India and the AstraZeneca-SKBio of South Korea.
The CanSino vaccine is based on a viral vector to administer DNA to elicit an immune response, a technique similar to that used in both AstraZeneca and Johnson & Johnson (JNJ.N) vaccines that are being investigated for their association with very rare blood clots combined with low platelets. counts.
CanSino said there have been no reports of blood clots. Read more
The Sinovac vaccine, which is used in places like Hong Kong and Brazil, relies on inactivated coronaviruses to generate an immune response, a technique used for decades, even against polio. Read more
Our standards: the principles of trust of Thomson Reuters.